Adult Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk.
The study will last about 108 weeks and may include up to 30 visits.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have type 2 diabetes mellitus (T2DM)
-Participant must be on stable treatment dose of at least 1 and no more than 3 oral antihyperglycemic drugs
-Participant must have increased risk for cardiovascular events
-Participant must be of stable weight
-Participant must not have type 1 diabetes mellitus (T1DM)
-Participant must not have pancreatitis
-Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
-Participant must not have acute or chronic hepatitis or symptoms of any other liver disease
-Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
-Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months